Eprova AG
Records under this name other than patents Eprova AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,318,745 | Crystalline Forms of (6R)-L-ERYTHRO-TETRAHYDROBIOPTERIN Dihydrochloride Formerly held Term ended Term ended Nov 17, 2024 · High confidence | Term ended | Term ended Nov 17, 2024 | High confidence |
| US 6,441,168 | Stable crystalline salts of 5-methyltetrahydrofolic acid Formerly held Term ended Term ended Jul 30, 2022 · From the USPTO record | Term ended | Term ended Jul 30, 2022 | From the USPTO record |
| US 6,858,731 | Process for the Preparation of Pure Stereoisomers of Tetrahydrofolic Acid Ester Salts and Tetrahydrofolic Acid by Fractionated Crystallisation of Tetrahydrofolic Acid Ester Salts Formerly held Term ended Term ended Jul 19, 2020 · High confidence | Term ended | Term ended Jul 19, 2020 | High confidence |
| US 7,816,525 | Process for the Preparation of Optically Pure Tetrahydropterins and Derivatives, and Specifically of Optically Pure Tetrahydrofolic Acid and Derivatives Thereof, by Stereospecific Hydrogenation Formerly held Term ended Term ended Jul 12, 2020 · High confidence | Term ended | Term ended Jul 12, 2020 | High confidence |
| US 6,544,994 | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase Formerly held Term ended Term ended Jun 7, 2020 · From the USPTO record | Term ended | Term ended Jun 7, 2020 | From the USPTO record |
| US 6,995,158 | Pharmaceutical Preparation Containing at Least Folic Acid or a Folate and Tetrahydrobiopterin (BH4) or Derivatives Thereof Used for the Treating or Preventing Cardiovascular or Neurological Disorders by Modulation of the Activity of Nitric Oxide Synthase (NOS) Term ended Ended no later than Jun 7, 2020 · Low confidence | Term ended | Ended no later than Jun 7, 2020 | Low confidence |
| US 6,011,040 | Use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for influencing the homocysteine level, particularly for assisting the remethylation of homocysteine Formerly held Term ended Term ended Jun 11, 2018 · From the USPTO record | Term ended | Term ended Jun 11, 2018 | From the USPTO record |
| US 6,271,374 | Stable crystalline (6S)- and (6R)-tetrahydrofolic acid Formerly held Term ended Term ended Jan 26, 2018 · From the USPTO record | Term ended | Term ended Jan 26, 2018 | From the USPTO record |
| US 6,160,116 | Sodium salt of (6S)-folinic acid Term ended Term ended Dec 12, 2017 · From the USPTO record | Term ended | Term ended Dec 12, 2017 | From the USPTO record |
| US 6,194,600 | Method of producing aminocyanoacetamide Formerly held Lapsed on the fee record Ended Feb 27, 2013 · From the USPTO record | Lapsed on the fee record | Ended Feb 27, 2013 | From the USPTO record |